STOCK TITAN

Ensysce Biosciences Inc Stock Price, News & Analysis

ENSC Nasdaq

Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.

Ensysce Biosciences Inc (NASDAQ: ENSC) is a clinical-stage pharmaceutical innovator developing safer opioid therapies through its patented TAAP and MPAR technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in addressing prescription drug abuse.

Access real-time information about clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features press releases covering product development breakthroughs, intellectual property updates, and operational developments in pain management solutions.

Key content includes updates on abuse-deterrent formulation testing, FDA communication statuses, manufacturing collaborations, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while emphasizing patient safety advancements.

Bookmark this page for streamlined tracking of ENSC's mission to transform opioid therapy through biochemical innovation and rigorous clinical validation. Check regularly for verified updates directly from corporate communications and authorized news sources.

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) has locked its database for the oral Human Abuse Potential (HAP) study of PF614, a controlled-release oxycodone product, on February 24, 2023. This pivotal study is essential for obtaining Abuse Deterrent labeling from the FDA. Following unblinding on February 27, 2023, results are scheduled for release by the end of March 2023. The company leverages its Trypsin Activated Abuse Protection (TAAP) technology to develop safer pain management options that mitigate risks of abuse and overdose.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences (NASDAQ: ENSC), a clinical-stage biotech company, issued a letter from CEO Dr. Lynn Kirkpatrick addressing shareholder questions. The company aims to improve drug safety, specifically focusing on opioid analgesics to combat the opioid crisis. Ensysce's unique technology chemically modifies opioids to reduce abuse potential. In 2022, the company initiated four clinical studies, achieving positive results in three, with expectations for upcoming data on the fourth study.

As of September 30, 2022, Ensysce had $4.5 million in cash and has taken measures to manage potential dilution and cash burn while advancing its clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage biotech company, announced on February 14, 2023, that the Nasdaq Hearings Panel granted its request for continued listing on the Nasdaq Stock Market. This decision is contingent on the company meeting criteria for the Nasdaq Capital Market tier, including a minimum bid price of $1.00 and stockholders' equity of at least $2.5 million by June 12, 2023. Ensysce focuses on innovative drug safety technologies to combat prescription medication abuse and overdoses through its proprietary platforms, TAAP and MPAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced that Geoff Birkett, Chief Commercial Officer, will present at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C. The HEAL initiative focuses on improving treatment strategies for opioid misuse and enhancing pain management. Ensysce will showcase its MPARTM platform, which includes PF614-MPAR, the first opioid with both abuse deterrent and overdose protection properties. Dr. Lynn Kirkpatrick emphasized the significance of federal support in advancing their mission to combat opioid abuse and potentially save lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced the closure of a registered direct offering, selling 3,571,431 shares at $0.84 per share, generating approximately $3.0 million in gross proceeds. A concurrent private placement involved issuing warrants for the same number of shares with an exercise price of $0.715, which are immediately exercisable.

The proceeds are intended for general corporate purposes including capital expenditures, working capital, and debt repayment. The shares were offered under a previously filed effective registration statement with the SEC, which also included a prospectus for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
-
Rhea-AI Summary

Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced a registered direct offering of 3,571,431 shares of common stock at $0.84 per share, totaling approximately $3 million in gross proceeds. Concurrently, the company will issue warrants for 3,571,431 shares with an exercise price of $0.715, exercisable immediately for five and a half years. The offering is expected to close around February 6, 2023, pending standard conditions. Proceeds will be utilized for corporate purposes, including capital expenditures, working capital, and debt repayment. H.C. Wainwright & Co. serves as the exclusive placement agent for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
Rhea-AI Summary

Ensysce Biosciences has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock for each outstanding share of common stock as of February 13, 2023. The Series A Preferred Stock will carry voting rights related to a reverse stock split and other specific matters. Each share will have 1,000,000 votes per share and will be automatically redeemed if not present at the stockholders' meeting. Ensysce is focused on developing safer prescription drugs using its proprietary technologies to minimize abuse and overdose risks. Detailed information about the Series A Preferred Stock will be released in upcoming SEC filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences announces the initiation of the final stage of a Phase 1 study for PF614-MPAR, an innovative opioid with overdose protection features, aimed at enhancing pain management while reducing abuse risks. Conducted by Dr. Maria Bermudez at Quotient Sciences in Miami, this trial follows successful initial testing, demonstrating that PF614-MPAR can limit oxycodone release during overdose. With its dual safety mechanisms, PF614-MPAR is expected to address common abuse methods. CEO Lynn Kirkpatrick emphasizes the potential to revolutionize pain treatment with this breakthrough, targeting severely afflicted patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.61%
Tags
-
Rhea-AI Summary

Ensysce Biosciences announced that CEO, Dr. Lynn Kirkpatrick, will present at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on January 25, 2023, at 12:20 p.m. Eastern Time. Ensysce, operating under the ticker symbols ENSC and ENSCW, is a clinical-stage biotech company developing tamper-proof prescription drugs to reduce abuse and overdose risk. The presentation will be followed by a Q&A session, and a live webcast will be available. Ensysce utilizes proprietary platforms, such as TAAP and MPAR, to create safer treatment options for severe pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
conferences
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) issued its 2023 shareholder letter, highlighting significant progress in clinical programs aimed at combating opioid abuse and overdose. The company reported positive clinical results and is advancing its lead product, PF614, through various studies. Ensysce's technology platforms, TAAP and MPAR, are designed to enhance drug safety while addressing the opioid crisis. Financially, the company secured $8 million via convertible notes and closed a $4.1 million public offering. Future clinical data is expected in early 2023, reinforcing Ensysce's commitment to improving prescription drug safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none

FAQ

What is the current stock price of Ensysce Biosciences (ENSC)?

The current stock price of Ensysce Biosciences (ENSC) is $2.31 as of July 3, 2025.

What is the market cap of Ensysce Biosciences (ENSC)?

The market cap of Ensysce Biosciences (ENSC) is approximately 5.3M.
Ensysce Biosciences Inc

Nasdaq:ENSC

ENSC Rankings

ENSC Stock Data

5.26M
2.27M
0.83%
10.02%
2.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA